Trial Condition(s):
Atrial Fibrillation
Survey on Belgian patients suffering from irregular heartbeat and starting treatment with a drug to prevent blood clots in blood vessels and the heart. This study is also called BELANCOS. (BELANCOS)
Bayer Identifier:
21153
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
In this study researchers want to learn more about the patient’s and treating doctor’s concerns about possible bleedings during treatment with drugs preventing blood clots in blood vessels and the heart – so called blood thinner. The study also wants to find out more about the patient’s knowledge on the importance, risks and benefits of treatment with this drug group.
Patients with irregular heartbeat not caused by valvular heart disease who will start treatment with a blood thinner will be asked by their treating cardiologist to complete a questionnaire related to their knowledge and fear of possible bleedings or stroke (blockage or rupture of a blood vessel to the brain) due to the intake of a blood thinner. The treating doctor will complete a similar questionnaire. The study plans to involve 15 cardiologists and 300 patients in Belgium.
Inclusion Criteria
- Male or female adult patients diagnosed with NVAF. - NOAC treatment-naive patients who will start a NOAC treatment.
Exclusion Criteria
- Previous stroke or thrombosis - Previous severe bleeding
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many locations Many locations, Belgium | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
BELgian ANtiCOagulation Survey for NVAF patients
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
Other
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Age categories of patientsCollected via the questionnaire.Timeframe: 1 day
- Gender (Female or male) of patientsCollected via the questionnaire.Timeframe: 1 day
- Patients' level of agreement with various statements of using NOACs in generalBy using a 5-point Likert scale (completely disagree, more likely to disagree, no opinion, more likely to agree, completely agree)Timeframe: 1 day
- Level of patients fear of having a bleeding on a scale from 0 - 10Timeframe: 1 day
- Level of patients fear of having a stroke or thrombosis on a scale from 0 - 10Timeframe: 1 day
- Age categories of physiciansCollected via the questionnaire.Timeframe: 1 day
- Gender (Female or male) of physiciansCollected via the questionnaire.Timeframe: 1 day
- Physicans' level of agreement with various statement of using NOACs in generalBy using a 5-point Likert scale (completely disagree, more likely to disagree, no opinion, more likely to agree, completely agree)Timeframe: 1 day
- Level of patients fear of having a bleeding assessed by physicans on a scale from 0 - 10Timeframe: 1 day
- Level of patients fear of having a stroke or thrombosis assessed by physicians on a scale from 0 - 10Timeframe: 1 day
Additional Information
Copyright © Bayer
Powered by
